An observational study in Acute Porphyrias and Cutaneous Porphyrias, sponsored by The American Porphyrias Expert Collaborative. Recruiting at 16 sites in United States. Open to participants aged 1 Minute and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by The American Porphyrias Expert Collaborative · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Porphyria, Acute Intermittent with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Porphyria, Acute Intermittent · United States.
Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, this one is the only one that started in 2010, is one of 6 observational ones, and was the 2nd registered.
21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.
Browse Porphyria, Acute Intermittent studies →2 of the 12 studies in Porphyria, Acute Intermittent with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Porphyria, Acute Intermittent studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 1 Minute and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2
First in 2003; this study’s year is marked. 1 started in 2010.
Median enrollment 28 across the 6 interventional studies, 149 across the 6 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 7 most frequent:
This is the only study on the registry with The American Porphyrias Expert Collaborative as lead sponsor.
The American Porphyrias Expert Collaborative has 1 study filed under Porphyria, Acute Intermittent — fewer than ten, so there is no comparison to draw.
1 of the studies in Porphyria, Acute Intermittent with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02935400The University of Texas Medical Branch, GalvestonAcute Porphyria Biomarkers for Disease Activity | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
The porphyrias are a group of rare metabolic diseases that may present in childhood or adult life and are due to deficiencies of enzymes in the heme biosynthetic pathway. The most common manifestations are related to accumulation of intermediates in the pathway and usually occur as acute neurological attacks, or cutaneous photosensitivity. Multiple mutations have been identified in each of the porphyrias. The risk of disability or death from these disorders is significant, in part because diagnosis is often delayed due to lack of adoption of diagnostic testing in clinical practice. Moreover, the natural history of these disorders is not well described and it is not known what determines differences in outcomes. New therapies are needed. For existing therapies, high-quality evidence on short and long term efficacy and safety is generally lacking. Therefore, the purpose of this long-term follow-up study of a large group of patients with the various porphyrias is to provide a better understanding of the natural history of these disorders, as affected by available therapies, and to aid in developing new forms of treatment.
The Office of Rare Diseases (ORD) of the National Institutes of Health (NIH) established a Rare Diseases Clinical Research Network (RDCRN) in collaboration with other NIH Institutes and currently has funded several rare diseases clinical research consortia and one Data Management and Coordinating Center. The Porphyrias Consortium was created as part of the RDCRN, to study the human porphyrias. The Porphyrias Consortium is a consortium of the academic institutions listed in the participating institutions table. All Centers in the Porphyrias Consortium are participating in the Longitudinal Study of the Porphyrias. Additional centers may be added if funding is available.
The initial objective of this protocol is to assemble a well-documented group of patients with confirmed diagnoses of specific porphyrias for clinical, biochemical, and genetic studies. The long-term objective is to conduct a longitudinal investigation of the natural history, complications, and therapeutic outcomes in people with acute and cutaneous porphyria.
Subjects will be recruited from the following resources:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For each type of porphyria, the inclusion criteria are based on
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with a documented diagnosis of AIP
Patients with a documented diagnosis of HCP
Patients with a documented diagnosis of VP
Patients with a documented diagnosis of CEP
Patients with a documented diagnosis of HEP
Patients with a documented diagnosis of PCT
Patients with a documented diagnosis of EPP
Patients with a documented diagnosis of XLP
Patients with a documented diagnosis of ALAD, ADP
Patients with a documented diagnosis of Homozygous Dominant AHP
clinical analysis
To develop disease severity scores to describe the combined frequency and severity of disease manifestations, utilizing linear mixed effects models \& stratification by age of onset.
Time frame: baseline
Laboratory analysis
To evaluate porphyrin and porphyrin precursor levels alone or by genotype and porphyria subtype
Time frame: baseline
Relationship between disease severity and biomarkers
To develop longitudinal models that relate, for example, porphyrin and porphyrin precursor levels alone or in concert with age, genotype and other features to the disease manifestation frequency.
Time frame: baseline
Effectiveness and tolerability of currently used and new therapies for the human porphyrias
Qualitative evaluation, using self-reporting questionnaires and clinical findings, and quantitative evaluation, using laboratory measures of organ function and porphyrin levels, to evaluate the effectiveness of therapies.
Time frame: baseline
Not enrolling at this site.
Started Nov 2010 (actual). Primary completion is estimated for Jun 2030, 235 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Porphyria, Acute Intermittent →